Brepocitinib Overview & RVT-3101 Update

2023: Roivant's Biggest Year Yet VTAMA (tapinarof) cream 1% r Expanded VTAMA Coverage and Reach VTAMA Phase 3 Readout in AD RVT-3101 (Anti-TL1A) UC Phase 2b Data Ongoing 1H 2023 1H 2023 ༧ང་ IMVT-1402 (Next-Gen Anti-FcRn) Human Data Mid-2023 Brepocitinib (TYK2/JAK1) Pivotal Trial Readout in SLE 2H 2023 Ongoing coverage expansion expected to increase net yield and add revenue Positive readout would pave way to atopic dermatitis market, which is ~4x the size of psoriasis market Positive final data from global Phase 2b would validate best-in-class potential Two potentially best-in- class anti-FcRn antibodies with deeper IgG reduction and simple subQ dosing give flexibility to maximize value across indications If positive could serve as one of two registrational trials in a large market with high unmet need roivant References are to calendar years. 27 For investor audiences only

View entire presentation